Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 39 min ago
PreprintCC BY-NC-NDmedRxiv

National trends, demographic disparities, and phenotypic shifts in encephalopathy-associated mortality in the United States: A CDC WONDER analysis, 1999-2024

  1. 1Ondokuz Mayiz University

Abstract

Encephalopathy is a lethal manifestation of global cerebral dysfunction spanning hypoxic, metabolic, toxic, and vascular etiologies, yet its population burden is difficult to quantify because it predominantly appears as a contributing rather than underlying cause of death. Here, we analyzed US multiple-cause death records from 1999 through 2024 using harmonized CDC WONDER datasets. A longitudinally consistent core definition of 10 ICD-10 codes identified 953,846 encephalopathy-associated deaths. The national age-adjusted mortality rate increased 28.4%, from 9.143 per 100,000 in 1999 to 11.738 in 2024, after peaking at 14.391 in 2021. Segmented log-linear regression identified four temporal phases: 1999-2004 (annual percent change [APC],-1.76%), 2004-2018 (APC, 2.57%), 2018-2021 (APC, 6.54%), and 2021-2024 (APC, -5.98%). Encephalopathy was listed as the underlying cause in only 21.6% of deaths in 2024. Unspecified encephalopathy surged more than 3.6-fold, while anoxic brain injury remained stable. Mortality remained higher in males than females (13.973 versus 9.778 per 100,000), and rates among non-Hispanic Black individuals were 1.90-fold those of non-Hispanic White individuals. Geographically, mortality clustered in the Midwest and South (13.144 and 13.120 per 100,000 in 2024), with persistent state-level dispersion across the study period. COVID-19 accounted for 10.9% of associated deaths in 2021 before falling to 1.4% in 2024. These findings reveal a nonlinear trajectory shaped by diagnostic shifts, pandemic disruption, and persistent demographic and geographic disparities.

Related

  1. Demographic and geographic disparities in mortality among U.S. adults with osteomyelitis: a CDC WONDER analysis, 1999-2023.
    Cinthiya Chander, John Paul Braun, Vikram Murugan +2
    BMC infectious diseasesPeer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMCPMC
  2. Temporal trends and socio-demographic disparities in COPD–lung cancer co-occurrence mortality in the United States: a 22 year analysis (1999–2020)
    Abdullah Nadeem, Syed Muhammad Asjad Rizvi, Areeba Aamir Ali Basaria +6
    Journal of Cancer Research and Clinical OncologyPeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicinePMC
  3. Prevalence and age, health insurance coverage and health facility level disparities associated with mistreatment of pregnant women during childbirth services in Tanzania: analysis of demographic and health survey 2022
    Pankras Luoga, Yi Xia, Jiayan Huang
    Reproductive HealthPeer-reviewedCC BY-NC-ND 4.0Full textObstetrics, gynaecology & paediatricsPMC
  4. Temporal trends and disparities in mesenteric ischemia–associated cardiovascular mortality among U.S. adults aged ≥45 years, 1999–2023
    Muhammad Atif Mazhar, Taha Alam, Yusra Fazli +8
    Frontiers in cardiovascular medicinePeer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMCCrossref
  5. Temporal trends and disparities in mortality associated with heart failure and underlying ischemic heart disease in the US population : A Nationwide retrospective cross-sectional study (1999–2023)
    Naveed Ahmad, Syed Tawassul Hassan, Syeda Lyba Onaiz +10
    MedicinePeer-reviewedCC BY-NCFull textGeneral medicineEurope PMCPMC
BibTeX
@misc{hamed2026national,
  title = {{National trends, demographic disparities, and phenotypic shifts in encephalopathy-associated mortality in the United States: A CDC WONDER analysis, 1999-2024}},
  author = {K. J. A. Hamed and M. A. Sayah and R. M. Bundid},
  howpublished = {medRxiv},
  year = {2026},
  month = sep,
  doi = {10.64898/2026.09.21.26363584},
  url = {https://www.medrxiv.org/content/10.64898/2026.09.21.26363584v1},
  note = {CC BY-NC-ND},
}
RIS
TY  - UNPB
TI  - National trends, demographic disparities, and phenotypic shifts in encephalopathy-associated mortality in the United States: A CDC WONDER analysis, 1999-2024
AU  - K. J. A. Hamed
AU  - M. A. Sayah
AU  - R. M. Bundid
PY  - 2026
DA  - 2026/09/21
PB  - medRxiv
DO  - 10.64898/2026.09.21.26363584
UR  - https://www.medrxiv.org/content/10.64898/2026.09.21.26363584v1
AB  - Encephalopathy is a lethal manifestation of global cerebral dysfunction spanning hypoxic, metabolic, toxic, and vascular etiologies, yet its population burden is difficult to quantify because it predominantly appears as a contributing rather than underlying cause of death. Here, we analyzed US multiple-cause death records from 1999 through 2024 using harmonized CDC WONDER datasets. A longitudinally consistent core definition of 10 ICD-10 codes identified 953,846 encephalopathy-associated deaths. The national age-adjusted mortality rate increased 28.4%, from 9.143 per 100,000 in 1999 to 11.738 in 2024, after peaking at 14.391 in 2021. Segmented log-linear regression identified four temporal phases: 1999-2004 (annual percent change [APC],-1.76%), 2004-2018 (APC, 2.57%), 2018-2021 (APC, 6.54%), and 2021-2024 (APC, -5.98%). Encephalopathy was listed as the underlying cause in only 21.6% of deaths in 2024. Unspecified encephalopathy surged more than 3.6-fold, while anoxic brain injury remained stable. Mortality remained higher in males than females (13.973 versus 9.778 per 100,000), and rates among non-Hispanic Black individuals were 1.90-fold those of non-Hispanic White individuals. Geographically, mortality clustered in the Midwest and South (13.144 and 13.120 per 100,000 in 2024), with persistent state-level dispersion across the study period. COVID-19 accounted for 10.9% of associated deaths in 2021 before falling to 1.4% in 2024. These findings reveal a nonlinear trajectory shaped by diagnostic shifts, pandemic disruption, and persistent demographic and geographic disparities.
ER  -